



# JENNIFER LE

PharmD, MAS, BCPS-ID, FIDSA, FCCP, FCSHP

Dr. Le is Professor of Clinical Pharmacy at the University of California at San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Her curriculum vitae, herein, describes her professional achievement during her academic career spanning 17 years.

## CONTACT

Address  
Email and Phone  
Faculty Website  
Residency Website  
Social Media

9500 Gilman Drive, MC 0657, La Jolla, CA 92093-0714

[jenle@ucsd.edu](mailto:jenle@ucsd.edu) and (858) 534 - 3692

<https://pharmacy.ucsd.edu/faculty/bios/le.shtml>

<http://www.memorialcare.org/long-beach-memorial>

Skype [jenleucsd](#), Twitter [@idpedle](#), LinkedIn, Research Gate, E-Scholarship

## EMPLOYMENT

July 2015 - Present

### PROFESSOR OF CLINICAL PHARMACY

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
La Jolla, California

Dec 2016 - Present

### DIRECTOR OF EXPERIENTIAL EDUCATION

Los Angeles and Orange County  
University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences

April 2002 – Present

### FACULTY-IN-RESIDENCE

Miller Children's & Women's and Long Beach Memorial  
Hospitals  
MemorialCare Health System, Long Beach, California

July 2011 – June 2015

### ASSOCIATE PROFESSOR OF CLINICAL PHARMACY

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences

La Jolla, California

June 2009 – June 2011

**ASSISTANT PROFESSOR OF CLINICAL PHARMACY**

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
La Jolla, California

July 2008 – May 2009

**ASSOCIATE PROFESSOR OF CLINICAL PHARMACY**

Western University of Health Sciences, College of Pharmacy  
Pomona, California

April 2002 – June 2008

**ASSISTANT PROFESSOR OF CLINICAL PHARMACY**

Western University of Health Sciences, College of Pharmacy  
Pomona, California

June 2001 – June 2011

**ASSISTANT PROFESSOR OF CLINICAL PHARMACY (WITHOUT SALARY)**

University of California San Francisco, School of Pharmacy  
San Francisco, California

**EDUCATION**

---

1991 – 1995

**BACHELOR OF SCIENCE, BIOLOGY**

University of California Los Angeles, Los Angeles, California

1996 – 2000

**DOCTOR OF PHARMACY**

University of California San Francisco, School of Pharmacy  
San Francisco, California

2000 – 2001

**PHARMACY PRACTICE RESIDENCY**

Long Beach Memorial and Miller Children’s & Women’s and Hospitals  
MemorialCare Health System, Long Beach, California

2011 – 2012

**MASTERS OF ADVANCED STUDIES, CLINICAL RESEARCH**

University of California San Diego, La Jolla, California

**LICENSURE & BOARD CERTIFICATION**

---

1996 - Present  
2000 – Present

**BASIC CARDIAC LIFE SUPPORT & FIRST AID**, American Heart Association  
**LICENSED PHARMACIST**, California Board of Pharmacy

2002 – Present	<b>HUMAN RESEARCH SUBJECTS PROTECTION TRAINING CERTIFICATION</b> , National Institutes of Health
2005	<b>NATIONAL PROVIDER IDENTIFIER</b> 1356346035, National Plan & Provider Enumeration System
2006	<b>PHARMACY-BAED IMMUNIZATION DELIVERY CERTIFICATION</b> , American Pharmacists Association
2007 – 2014	<b>CERTIFICATION IN PHARMACOTHERAPY</b> , Board of Pharmaceutical Specialties
2008 – 2015	<b>QUALIFICATION IN INFECTIOUS DISEASES</b> , Board of Pharmaceutical Specialties
2010 – Present	<b>COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE</b> in The Protection of Human Research Subjects and Good Clinical Practice
2014 – Present	<b>BOARD RE-CERTIFICATION IN PHARMACOTHERAPY</b> , Board of Pharmaceutical Specialties
2015 – Present	<b>BOARD QUALIFICATION IN INFECTIOUS DISEASES</b> , Board of Pharmaceutical Specialties
2018	<b>CERTIFICATE OF COMPLETION</b> , Faculty Mentorship Training Program, University of California San Diego Health Sciences Office of Faculty Affairs
2019	<b>CERTIFICATE OF COMPLETION</b> , Faculty Leadership Academy, University of California San Diego Office of Academic Affairs, Academic Personnel Services

## HONORS & AWARDS

---

2006	<b>MEMBERSHIP AWARD</b> American College of Clinical Pharmacy for membership recruitment as President of Southern California College of Clinical Pharmacy
2008	<b>RHO CHI HONOR SOCIETY</b> Western University, College of Pharmacy
2009	<b>FACULTY SERVICE AWARD</b> Western University, College of Pharmacy
2009 – Present	<b>ACADEMIC SENATE TRAVEL AWARD</b> University of California San Diego
2010	<b>RESEARCH AWARD</b> Complications Associated with <i>S. aureus</i> Bacteremia in Children Long Beach Research Symposium
2011	<b>FELLOW OF AMERICAN COLLEGE OF CLINICAL PHARMACY</b>

2012	<b>BEST POSTER AWARD</b> Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients, Fourth Regional Congress of Cancer and Blood Disorders of Childhood, Jordan Society of Oncology Pediatrics
2013	<b>FELLOW OF CALIFORNIA SOCIETY OF HEALTH-SYSTEMS PHARMACISTS</b>
2013	<b>RECOGNITION AWARD FOR OUTSTANDING MENTOR</b> University of California San Diego, Faculty Mentor Program
2017	<b>FELLOW OF INFECTIOUS DISEASES SOCIETY OF AMERICA</b>
2018	<b>STERNFELS PRIZE FOR DRUG SAFETY INNOVATION</b> <a href="http://sternfelsprize.org/">http://sternfelsprize.org/</a>

## CONTRACTS & GRANTS

July 2007 – Dec 2008	<b>PFIZER, INC</b> , <i>Complications Associated with Outpatient Parenteral Antibiotic Therapy in Children</i> , Principal Investigator (8% effort) of Investigator-Initiated Study, \$32,125
Oct 2007 – Dec 2009	<b>AMERICAN COLLEGE OF CLINICAL PHARMACY</b> , <i>Optimizing Outcomes of Gram-negative Infections with Translational Research</i> , Principal Investigator (20% effort) of Investigator-Initiated Study, \$20,000
March 2008 – May 2009	<b>MEMORIAL MEDICAL CENTER FOUNDATION</b> , <i>Treatment outcomes of urinary tract infection caused by multi-drug resistant Enterobacteriaceae</i> , Principal Investigator (5% effort) of Investigator-Initiated Study, \$3,120
Jan 2009 – May 2009	<b>ASTELLAS</b> , <i>Effects of Delayed Initiation of Antifungal Therapy in Critically-Ill Neonates with Invasive Candidiasis</i> , Principal Investigator (5% effort) of Investigator-Initiated Study, \$40,948
Jan 2009 – Dec 2009	<b>MEMORIAL MEDICAL CENTER FOUNDATION</b> , <i>Correlation Between Risk Factors and Outcomes in Critically Ill Infants with Invasive Candidiasis</i> , Principal Investigator (5% effort) of Investigator-Initiated Study, \$3,330
Feb 2009 – Dec 2011	<b>MEMORIAL MEDICAL CENTER FOUNDATION</b> , <i>Longitudinal Surveillance of Antibiotic-Resistant Pathogens Causing Nosocomial Infections: Epidemiologic and Clinical Implications</i> , Principal Investigator (2% effort) of Investigator-Initiated Study, \$18,720
Jan 2010 – Dec 2010	<b>CUBIST</b> , <i>Complications associated with Staphylococcus aureus bacteremia</i> , Principal Investigator (20% effort) of Investigator-Initiated Study, \$50,252
Jan 2010 – Dec 2010	<b>NATIONAL INSTITUTES OF HEALTH: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</b> , <i>Pharmacokinetics-pharmacodynamics of antimicrobials in pediatric resistant infections (K23)</i> , Principal Investigator (75-80% effort) of Investigator-Initiated Study, \$604,250
Sept 2011 – Aug 2016	<b>NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT</b> , <i>Developmental</i>

Feb 2011 – Present

*and Translational Pharmacology of Pediatric Antimicrobial Therapy (U54), Co-Investigator (5% effort) of Investigator-Initiated Project, \$3,734,148*

**JMI LABORATORIES**, SENTRY Antimicrobial Surveillance Program, Principal Investigator (2% effort) of Investigator-Initiated Study, \$80,000

Dec 2012 – Aug 2014

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Pharmacokinetics of Understudies Drugs Administered to Children per Standard of Care*, Co-Investigator(20% effort) of Investigator-Initiated Project, \$486,700

June 2015 – May 2016

**PRIVATE DONOR**, *Ceftaroline Pharmaockinetics in Children with Cystic Fibrosis*, Co-Investigator (10% effort) of Investigator-Initiated Study, \$20,000

May 2016 – April 2021

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics (T32)*, Co-Investigator (5% effort) of Investigator-Initiated Project, \$828,245

Sept 2016 – June 2021

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Specialized Centers in Research in Pediatric Developmental Pharmacology (RPDP, U54)*, Co-Investigator (5% effort) of Investigator-Initiated Project, \$3,872,907

April 2017 – June 2017

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (POPS) III*, Site Principal Investigator (Subcontract with Duke University, 20% effort) of Investigator-Initiated Project, \$4,545

Aug 2018 – July 2019

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Pediatric Trials Network’s Antibiotic Safety in Infants with Complicated Intra-abdominal Infections (PTN SCAMP Task Order #25)*, Site Principal Investigator (Subcontract with Duke University, 20% effort) of Investigator-Initiated Project, \$138,023

Aug 2018 – July 2019

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Duke University’s Pediatric Trials Network’s Antibiotic Safety in Infants with Complicated Intra-abdominal Infections (PTN SCAMP Task Order #25)*, Principal Investigator (20% effort) of Investigator-Initiated Project, \$138,023

Aug 2018 – June 2022

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Longitudinal Assessment of Beta-lactam Antibiotic Exposure in in Critically-Ill Children with Sepsis in the PICU to Predict Dosing Requirements (RO1)*, Colinvestigator of Investigator-Initiated Project (14% effort), \$1,885,634

## UNFUNDED RESEARCH

2001	Pilot Study of Discrepancy Errors in the Medication-Use System, Principal Investigator of Investigator-Initiated Study
2002	Evaluation of the Management of Pyelonephritis in Obstetric Patients, Principal Investigator of Investigator-Initiated Study Retrospective Study of Insulin Management in Diabetic Obstetric Patients, Co-Investigator
2003	Safety and Tolerability of Amphotericin B Use in Neonates, Principal Investigator of Investigator-Initiated Study
2004	Evaluation of Disseminated Diseases in Neonates with Invasive Candidiasis, Principal Investigator of Investigator-Initiated Study Prospective Study and Implementation of Medication Reconciliation Process, Co-Investigator
2005	Analysis Adverse Drug Reactions in Hospitalized Pediatrics Patients over a 10-Year Period, Principal Investigator of Investigator-Initiated Study Evaluation of Appropriate Use of Vancomycin with the Calculation of Defined Daily Dose, Principal Investigator of Investigator-Initiated Study
2006	Impact of Initial Antibiotic Treatment on the Development of ESBL Infections in Neonates, Principal Investigator of Investigator-Initiated Study Risk Factors and Appropriateness of Antibiotic Therapy in Hospitalized Patients with Healthcare-Associated Pneumonia, Principal Investigator of Investigator-Initiated Study
2008	Characterization of Prior Antibiotic Use and Risk of Acquisition of ImipenemResistant <i>Acinetobacter baumannii</i> , Principal Investigator of Investigator-Initiated Study Evaluation of a Revised Pediatric Vancomycin Pharmacokinetic Guideline in the Treatment of Presumed or Confirmed Methicillin-Resistant <i>Staphylococcus aureus</i> (Investigator-initiated study), Co- Investigator
2009	Hepatotoxicity Associated with Fluconazole in Critically-ill Infants, Principal Investigator of Investigator-Initiated Study Cough and Cold Medications Use in Children: Pharmacists' Perspectives, Principal Investigator of Investigator-Initiated Study
2013	Combination Antifungal Therapy in Children, Principal Investigator of Investigator-Initiated Study
2014	Medication Errors in Children and Adults: A Comparative Study, Principal Investigator of Investigator-Initiated Study
2015	Role of Hospital Discharge Education by Pharmacists, Principal Investigator of Investigator-Initiated Study

2016 Augmented Renal Clearance in Children: Vancomycin Pharmacokinetic Modeling, Principal Investigator of Investigator-Initiated Study  
Risk Factors Associated with Augmented Renal Clearance in Children, Principal Investigator of Investigator-Initiated Study

**MEMBERSHIP**

---

1998 – 2015	<b>American Society of Health-System Pharmacists</b>
1998 – 2010	<b>American Pharmaceutical Association</b>
2000 – Present	<b>California Society of Health-System Pharmacists</b>
2001 – Present	<b>American College of Clinical Pharmacy</b> , Infectious Diseases and Pediatrics Pharmacy Research Network
2002 – 2004	<b>American Association of Colleges of Pharmacy</b>
2004 – 2014	<b>Southern California Chapter of College of Clinical Pharmacy</b>
2004 – 2010	<b>California Pharmacists Association</b>
2006 – Present	<b>Society of Infectious Diseases Pharmacists</b>
2006 – 2010	<b>Central Los Angeles Pharmacists Association</b>
2006, 2008 – 2012	<b>American Society of Microbiology</b>
2008 – Present	<b>Infectious Disease Association of California</b>
2010 – Present	<b>Infectious Diseases Society of America (Full Member)</b>

**EDITORIAL BOARD**

---

2010 – 2013	<b>EDITORIAL BOARD MEMBER</b> , Infectious Diseases Section, Pediatric Pharmacotherapy, Editors Milap Nahata and Sandra Caballero, American College of Clinical Pharmacy
2011 – 2012	<b>EDITOR</b> , Infectious Diseases Section, Pediatric Pharmacotherapy, American College of Clinical Pharmacy, 2013 (Chapter 45, 708-717)
2015 – 2017	<b>INVITED EDITORIAL FACULTY PANEL CHAIR</b> , Pediatric Self-Assessment Program (PedSAP) 2016 Book 1 (Immunology), American College of Clinical Pharmacy
2017 – 2020	<b>INVITED EDITORIAL BOARD MEMBER</b> , Pharmacotherapy, Areas of Expertise in Pediatrics, Infectious Diseases, Pharmacokinetics, and Pharmacodynamics American College of Clinical Pharmacy

**CONSULTATION & ADVISORY BOARD**

---



2008 – 2012	<b>CONSULTANT</b> , Infectious Diseases for Network of Advisors (c/o Clinical Advisors), New York, NY
2006 – 2010	<b>CONSULTANT AND MEMBER OF SPEAKERS BUREAU</b> , Infectious Diseases for Pfizer Pharmaceuticals (Eraxis®, V-fend®, Zyvox®), New York, NY
2008	<b>EDITORIAL ADVISORY BOARD MEMBER</b> , California Society of Health-System Pharmacists
2009 – 2010	<b>CONSULTANT</b> , Antimicrobial Stewardship for Children’s Hospital of Orange County, Orange, CA
2013 – 2014	<b>CONSULTANT</b> , Compass Point Research, Nashville, TN
2014 – 2015	<b>BIostatistician AND CLINICAL ANALYST</b> , Compass Point Research, Nashville, TN
2015	<b>CONSULTANT</b> , National Science Centre, Poland
2015 – Present	<b>MEMBER</b> , SDPharmNet, San Diego, CA
2013 – 2019	<b>CONSULTANT</b> , Therapeutic Drug Monitoring, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam
2016 – 2017	<b>CONSULTANT</b> , Pharmacy Operations, Children’s Hospital #2, Ho Chi Minh City, Viet Nam
2017	<b>CONSULTANT</b> , Antibiotic Stewardship at Long An General Hospital, Ho Chi Minh City, Viet Nam
2017 – Present	<b>INVITED ADVISORY BOARD MEMBER</b> , <i>Infectious Diseases and Therapy Journal</i>
2018 – 2020	<b>INVITED ADVISORY BOARD MEMBER</b> , Antimicrobial Drugs Advisory Committee, United States Food and Drug Administration
2018 – Present	<b>INVITED ADVISORY BOARD MEMBER</b> , Asian Pacific Health Foundation

**JOURNAL & BOOK REVIEW**

2003 – Present 2004	Pharmacotherapy Journal of the American Pharmacists Association (JAPhA) Formulary
2007 – Present 2009	Pediatric Infectious Diseases Journal Critical Care Medicine Feature Coordinator for California Journal of Health-Systems Pharmacist Childhood Obesity Continuing Education Program Residency Pearls Journal of Global Infectious Diseases
2010 – 2011	Infectious Diseases (Book 9), Pharmacotherapy Self-Assessment Program, Seventh Edition



2011 – Present	Journal of Antimicrobial Chemotherapy
2012 – Present	Clinical Therapeutics
2013 – Present	Journal of Pharmacokinetics and Pharmacodynamics
	Journal of Pediatric Infectious Diseases
2014	Expert Review of Anti-infective Therapy
	Antimicrobial Agents and Chemotherapy
2015 – Present	Infectious Diseases and Therapy Journal
2016	Journal of Clinical Pharmacy and Therapeutics
	Journal of Global Antimicrobial Resistance
2018	Annals of Internal Medicine

**GRANT REVIEW**

2010	Medical Research Council, South Africa
2015	National Science Centre, Poland
2019	National Institutes of Health, Special Emphasis Panel/Scientific Review Group, Respiratory Sciences - Small Business Study Section
2019	National Institutes of Health, Study Section Microbiology and Infectious Diseases

**INVITED REVIEW**

2003	<b>REVIEWER</b> , California Society of Health-System Pharmacist
2004	<b>REVIEWER</b> , American Pharmacists Association (APhA)
2010	<b>REVIEWER</b> , Pharmacogenomics Education Program (PharmGenEd™), Expert Reviewer for Asthma
2012 – 2013	<b>PROMOTION FILE REVIEWER</b> , Faculty Promotion Review for Loma Linda University and Western University
2016	<b>REVIEWER</b> , American College of Clinical Pharmacy Self-Assessment Program (SAP)
2017 – Present	<b>PROGRAM REVIEWER</b> , American College of Clinical Pharmacy: Self-Assessment Programs including Pediatrics (PedSAP), Ambulatory Care (ACSAP), Pharmacotherapy (PSAP) & Cardiology
2019	<b>ABSTRACT REVIEWER</b> , Infectious Diseases Society of America, ID Week Resistance Mechanism
	<b>IN FILE REVIEWER</b> , Faculty Promotion Review for University at Buffalo School of Pharmacy and Pharmaceutical Sciences

**LEADERSHIP & SERVICE IN PROFESSIONAL COMMITTEES**

- 2001 – 2002 **VOLUNTEER**, California Society of Health-System Pharmacists Seminar
- 2002 – 2003 **FACULTY ADVISOR**, South-Bay Long Beach Society of Health-System Pharmacists, Quiz Bowl
- 2004 **MEMBER**, Awards and Scholarship Committee, Southern California College of Clinical Pharmacy
- 2004 **MODERATOR**, California Society of Health-System Pharmacists Seminar
- 2005 **LECTURER**, Southern California College of Clinical Pharmacy
- 2006 **MEMBER**, Southern California College of Clinical Pharmacy
- 2006 **FOUNDER AND COORDINATOR**, Southern California Infectious Diseases Pharmacists Working Group
- 2007 **MEMBER**, Southern California College of Clinical Pharmacy
- 2007 **FOUNDER AND CHAIR-ELECT**, Southern California College of Clinical Pharmacy Infectious Diseases Pharmacists Working Group
- 2007 **CHAIR**, Taskforce for Expert Opinion Paper on Aerosolized Antibiotics Society of Infectious Disease Pharmacists
- 2007 **INITIATOR AND DEVELOPER**, Awards and Recognition Program, Southern California College of Clinical Pharmacy
- 2007 **FACULTY VOLUNTEER**, 27<sup>th</sup> Annual Western States Conference
- 2007 **MEMBER**, Awards Committee, American College of Clinical Pharmacy
- 2008 **FOUNDING DEVELOPER**, Awards Committee, Southern California College of Clinical Pharmacy
- 2008 **CHAIR**, Southern California College of Clinical Pharmacy Infectious Diseases Pharmacists Working Group
- 2008 **ALTERNATE-DELEGATE**, House of Representatives, Orange County Society of Health-System Pharmacists
- 2008 **WORKFORCE MEMBER**, Program on Faculty Recruitment, Retention and Enrichment Sponsored by American Association of Colleges of Pharmacy
- 2008 **FOUNDING DEVELOPER AND INVITED GUEST TO DEAN'S COUNCIL, PARTICIPANT**, ACPE Focused Site Visit at Western University
- 2008 **EDITORIAL ADVISORY BOARD MEMBER**, California Society of Health-System Pharmacists
- 2008 **PARTICIPANT**, Focused-Investigator Training Program, American College of Clinical Pharmacy Research Institute
- 2008 – 2010 **MEMBER**, Aerosolized Antimicrobials Taskforce for Society of Infectious Diseases Pharmacists

- 2009 , California Society of Health-System Pharmacists Editorial Advisory Board  
**INVITED GUEST**, Graduate Education/Training in Experimental Pharmacotherapeutics Summit, American Association of Colleges of Pharmacy
- 2009 – 2010 **CHAIR**, Awards Committee, Southern California College of Clinical Pharmacy
- 2010 **HEAD CONTRIBUTOR**, Faculty Orientation and Development Information Guide, UCSD Skaggs School of Pharmacy - Faculty Development and Mentorship Committee  
**SECRETARY & TREASURER**, American College of Clinical Pharmacy, Infectious Diseases Practice and Research Network
- 2012 – 2013 **APPOINTED MEMBER**, Board of Pharmacy Specialties in Infectious Diseases Pharmacy Practice Analysis Taskforce

## LEADERSHIP & SERVICE

### UNIVERSITY OF CALIFORNIA SAN DIEGO

---

- 2009 – 2010 Faculty Development Committee, Comprehensive Exam Committee, Research Interest Group, Admissions Committee, Education Policy and Academic Oversight Committee
- 2010 – 2011 , Faculty Development and Mentorship Committee **MEMBER**, Campus-wide Associated Health Professions Education Committee, Library Committee, Comprehensive Exam Committee, Subcommittee of Educational Policy (CEP) for Microbiology/Immunology, Student Summer Research Committee, Research Interest Group, Education Policy and Academic Oversight Committee
- 2011 – 2012 **CHAIR**, Faculty Development and Mentorship Committee  
**MEMBER**, Campus-wide Associated Health Professions Education Committee, Comprehensive Exam Committee, Student Summer Research Committee, Member, Education Policy and Academic Oversight Committee, Campus-wide Committee for Master of Advanced Studies, Clinical Research Program Review, *Ad Hoc* Pharm.D./Ph.D. Committee
- 2012 – 2013 **CO-CHAIR**, Faculty Development and Mentorship Committee  
**MEMBER**, Campus-wide Associated Health Professions Education Committee, Comprehensive Exam Committee, Student Summer Research Committee, Education Policy and Academic Oversight Committee,

- 2013 – 2014 , Faculty Development and Mentorship Committee  
 Campus-wide Associated Health Professions Education  
 Committee, Faculty Awards Sub-committee, Comprehensive Exam  
 Committee, Student Summer Research Committee, Education Policy and  
 Academic Oversight Committee, Donor Stewardship Committee
- 2014 – 2015 , Campus-wide Associated Health Professions Education  
**CHAIR**, Faculty Awards Committee  
**CO-CHAIR**, Faculty Development and Mentorship Committee  
**MEMBER**, Faculty Awards Committee, Comprehensive Exam Committee,  
 Student Summer Research Committee, Education Policy and Academic  
 Oversight Committee, *Ad Hoc* SSPPS Research Retreat Planning  
 Committee, *Ad Hoc* Pharm.D./Ph.D. Committee
- 2015 – 2016 , Campus-wide Associated Health Professions Education  
**CHAIR**, Faculty Awards Committee  
**CO-CHAIR**, Faculty Development and Mentorship Committee  
**MEMBER**, Comprehensive Exam Committee, SSPPS APPE/IPPE Course  
 Committee (Sub-Committee for Committee on Educational Policy),  
 Student Summer Research Committee, Education Policy and Academic  
 Oversight Committee, *Ad Hoc* SSPPS Research Retreat Planning  
 Committee
- 2017 , Faculty Awards Committee  
**CHAIR**, Assessment Committee  
**MEMBER**, Committee on Educational Policy, Committee on Academic  
 Personnel, Comprehensive Exam Committee, Student Summer Research  
 Committee, International Collaboration and Education
- 2017 – 2018  
**CHAIR**, Assessment Committee  
**CHAIR**, ACPE Self-Study on Educational Outcomes and Assessment  
**MEMBER**, ACPE Self-Study Steering Committee, Committee on Academic  
 Personnel, Student Summer Research Committee, International  
 Collaboration and Education, SSPPS APPE/IPPE Course Committee (Sub-  
 Committee for Committee on Educational Policy), Ad-hoc Committee for  
 Fourth-Year Appraisal

**LEADERSHIP WESTERN UNIVERSITY, COLLEGE OF PHARMACY**

*Note: Member services were excluded*

- 2002 – 2003 , Scholarship Recognition and Award Committee
- 2003 – 2004 , Faculty Orientation, Enhancement, and Development  
**CHAIR**, Ad hoc Post-Faculty Retreat Committee  
**PROGRAM REVIEWER**, EdScholar Implementation
- 2004 – 2005 , Faculty Orientation, Enhancement, and Development  
**CHAIR**, ACPE Self-Study - Faculty Development Committee  
**SECRETARY**, Faculty Meetings  
**PROGRAM REVIEWER**, E-portfolio Implementation
- 2005 – 2007 , Pharmacy Faculty Assembly  
**MEMBER**, Dean’s Council and Committee for College of Pharmacy Mission Statement
- 2007 – 2009 **CHAIR**, Faculty Orientation, Enhancement, and Development  
**ASSESSOR**, Peer Formative Assessment of Teaching Program  
**MEMBER**, Mentorship Program

**HEALTH CARE CENTERS SERVICES AND COMMITTEES**

- 2002 – Present **FACULTY-IN-RESIDENCE**, Long Beach Memorial and Miller Children’s & Women’s Hospitals of Long Beach, MemorialCare Health System
- 2004 **INVITED PARTICIPANT**, Strategic Planning Committees for Missing Medications, Customer Service, Clinical Programs, Emergency Department & Technician Program, Long Beach Memorial and Miller Children’s & Women’s Hospitals of Long Beach
- 2003 – 2006 Women’s Hospitals of Long Beach, MemorialCare Health System  
**INITIATOR**, Inpatient Infectious Diseases Pharmacy Services, Long Beach Memorial and Miller Children’s & Women’s Hospitals of Long Beach,
- 2008 – 2009 **MEMBER**, Antimicrobial Stewardship Committee, Children’s Hospital of Orange County
- 2008 – 2009 **MEMBER**, Epidemiology Committee, Miller Children’s Hospital
- 2009 – Present **MEMBER**, Residency Oversight Committee, Long Beach Memorial Medical Center and Miller Children’s Hospital
- 2010 **CONTRIBUTOR**, PGY-1 Residency Re-accreditation Report, Long Beach Memorial Medical Center

- 2010 **MEMBER**, Residency Advisor Council, University of California San Diego Medical Center
- 2011 **MEMBER**, Memorialcare Health System, Academic Advisory Council
- 2012 **REVIEWER**, Memorialcare Health System Institutional Review Board
- 2013 **MEMBER**, Clinical Research Operations Task Force, Memorialcare Health System  
**MEMBER**, Clinical Research Operations Implementation Task Force Memorialcare Health System
- 2013 **MEMBER**, Clinical Research Managers Task Force, Memorialcare Health System
- 2014 **MEMBER**, pSCANNER Research Planning Roundtable, Memorialcare Health System  
**MEMBER**, Hospital Discharge and Transitional Care Pharmacist Program, Long Beach Memorial Hospital
- 2014– Present **MEMBER**, Long Beach Memorial Residency Advisory Committee

**CREATIVE PROGRAMS ESTABLISHED**

---

- 2002 **LEAD DEVELOPER**, Chemotherapeutic Agents Ordering and Monitoring Process, Long Beach Memorial Medical Center
- 2003 **DEVELOPER**, Revision of Instructor and Block Evaluations Western University of Health Sciences, College of Pharmacy
- 2003, 2005 **DEVELOPER**, Adult Digoxin Dosing Guideline for Pharmacist-Regulated Therapies, Long Beach Memorial Medical Center
- 2004 **DEVELOPER**, Best Practice Guideline for the Management of Pyelonephritis in Pregnant, Women Long Beach, Orange Coast, Saddleback and Anaheim Memorial Medical Centers  
**DEVELOPER**, Medication Reconciliation Program Long Beach Memorial Medical Center and Miller Children’s Hospital  
**INITIATOR AND DEVELOPER**, Cefepime in Neutropenic Pediatric Patients Miller Children’s Hospital
- 2005 **LEAD DEVELOPER**, Vancomycin Drug Utilization Evaluation Long Beach Memorial Medical Center  
**CONTRIBUTOR**, Maternal and fetal outcomes in the management of diabetic obstetric patients Long Beach Memorial Medical Center  
**INITIATOR AND DEVELOPER**, Adult intravenous Vancomycin Guideline for Pharmacist-Regulated Therapies Long Beach Memorial Medical Center
- 2006 – Present **INITIATOR, DEVELOPER AND DIRECTOR**, PGY-1 Pharmacy Practice

- Residency with Emphasis in Education and Research (in affiliation with UC San Diego) Long Beach Memorial Medical Center
- 2007 **INITIATOR AND DEVELOPER**, Clinical Pharmacist in the Emergency Department Long Beach Memorial Medical Center and Miller Children's
- CONTRIBUTOR**, University-wide Orientation Program Western University
- 2007 – 2008 **INITIATOR AND DEVELOPER**, Antibioqram Supplement Long Beach Memorial Medical Center and Miller Children's Hospital
- 2008 **INITIATOR AND ASSESSOR**, Peer Formative Assessment of Teaching Western University of Health Sciences, College of Pharmacy
- CONTRIBUTOR**, Mentorship Program (for Faculty Members) Western University of Health Sciences, College of Pharmacy
- 2009 **INITIATOR AND DEVELOPER**, Implementation of E-testing for *S. aureus* isolates and Implementation of modified Hodge's Test screening for KPC Long Beach Memorial Medical Center and Miller Children's Hospital
- 2009 – 2010 **INITIATOR AND DEVELOPER**, Antibioqram, Neonatal Antifungal and Sepsis Guidelines, Neutropenic Sepsis and Antifungal Guidelines, Restricted Antimicrobial Use Policy Children's Hospital of Orange County
- INITIATOR AND DEVELOPER**, Team-based Teaching and Medicine (APPE) Lesson Plan Long Beach Memorial Medical Center

## COMMUNITY & INTERNATIONAL SERVICES

- 2001 **PARTICIPANT**, Health Fair Expo at Long Beach Memorial Medical Center
- 2004 **COORDINATOR**, Pharmacy Booth, Miller Children's Annual Health Fair
- COORDINATOR**, Poison Control Booth, Baby Expo, Long Beach Memorial Medical Center
- 2007 **JUDGE**, Final Posters, Pharmacy Technician Poster Competition, American University of Health Sciences
- COORDINATOR**, Health Fair in El Monte for Hypertension and Diabetes Screening (APhA) and Ask Your Pharmacist (NCPA)
- 2010- 2016 **ADVISOR**, Summer Volunteer Program for High School and Pre-Pharmacy Students (Ivilynn Bui, Tri Tran, Gabriela Rodriguez, Tiana Vo, Austin Nguyen, Kelsey Schmidt, Andy Vo, and Alexandra Gionta), Long Beach Memorial
- 2013 **COLLABORATOR**, Food Insecurity Project, University of Wisconsin School of Pharmacy
- 2015 **PROGRAM INITIATOR, DEVELOPER AND IMPLEMENTOR**, Vancomycin Therapeutic Monitoring, Oxford University Clinical Research Unit and Hospital for Tropical Diseases in Viet Nam



2016 **PROGRAM INITIATOR, DEVELOPER AND IMPLEMENTOR**, Aminoglycosides Therapeutic Monitoring, Oxford University Clinical Research Unit and Hospital for Tropical Diseases in Viet Nam

2017 **PROGRAM INITIATOR AND DEVELOPER**, Access to Human Papilloma Virus Vaccine, Oxford University Clinical Research Unit in Viet Nam

INVITED LECTURE

**LOCAL**

2001 Gram-Positive Bacterial Infections: Pattern of Resistance and New Treatment, Long Beach Memorial Medical Center, 1 ACPE

2002 Faculty Retreat: Reframing Our Vision, Western University

2003 Ursodiol in the Treatment of Gallstones, Western University

2006 Management of Candidemia: Focus on New Therapies, Southern California College of Clinical Pharmacy, 1 ACPE

Fungal Diseases for the Clinician with a Focus on Candida Infection, Long Beach Memorial Medical Center, 1 CME

Disseminated Candidiasis in Neonates, Long Beach Research Symposium

2007 Risk Factors and Treatment of Candidemia, Pacific Hospital

Acute Otitis Media and the Role of Community Pharmacists, Orange County of Pharmacists Association, 1 ACPE

Acute Otitis Media, University of Southern California Physician Assistant Program

Fungal Infections in the Changing Hospital Environment, Pacific Hospital

2008 Burden of MRSA Infection – Focus on HA-MRSA, Pacific Hospital

Antifungal Guidance: Management Strategies and Practice Guideline, Pacific Hospital

2009 Update on Antifungal Agents, Pacific Hospital

2009 – 2014 Residency Seminar Series: Database Management, Statistical Analysis and Referencing for Research Projects

Residency Seminar Series: Teaching Opportunities During Residency

Residency Seminar Series: Career in Academia

Residency Seminar Series: Effective Precepting of Pharmacy Students During Acute Care Rotation

2011 Long Beach Memorial Medical Center & Miller Children’s Hospital

Is A Career in Pharmacy Right for You?, Muir’s Eventual Doctors University of California, San Diego

2014 – 2018 Residency Seminar Series: Academia and Pediatric Research

Residency Seminar Series: Generating Hypothesis in Research

Residency Seminar Series: Effective Precepting of Pharmacy Students

Residency seminar series: Study Design and Research Hypothesis  
 Residency Seminar Series: Database Management, Statistical Analysis and Referencing for Research Projects  
 Residency Seminar Series: Precepting Pearls and Assessment & Academic Pharmacy  
 Long Beach Memorial & Miller Children's and Women's Hospitals  
 2018 Academic Pharmacy in Pediatric Infectious Diseases: *From Bedside to Research and Back*, UC San Diego Pre-Pharmacy Society  
 Optimizing Drug Dosing in Pediatrics Through Clinical Pharmacology, Rady Children's Hospital of San Diego, Research Seminar Series

Career in Academic Pharmacy: Pediatric Infectious Diseases, UCSD Alpha Epsilon Delta Pre-Health Society, Annual Health Professional Symposium  
 Academic Pharmacy: Focus in Pediatric Pharmacology Research, UCSD Alpha Epsilon Delta Pre-Health Society, General Meeting

#### STATE

2000 CAL-OPTIMA Asthma Training, CAL-OPTIMA, 2 ACPE  
 2007 Community Pharmacists in the Management of Pediatric Infectious Diseases, California Pharmacists Association, 1.5 ACPE  
 2008 Update on Treatment of Candidemia, California Pharmacists Association, 1.5 ACPE  
 What Are You Doing to Treat and Prevent MRSA in Your Onstitution? - Discussion Panel, California Society of Health-System Pharmacists Seminar, 1 ACPE  
 2013 Therapeutic Drug Monitoring of Antimicrobial Agents in Children, California Society of Health-System Pharmacists Seminar, 1 ACPE

#### NATIONAL

2004 Urinary Tract Infections During Pregnancy (manuscript invited for CE), *Annals of Pharmacotherapy*, 1 ACPE  
 Management of Bacterial Rhinosinusitis (manuscript invited for CE), *American Journal of Managed Care*, 2 CME/ACPE  
 2005 Therapeutic Management of Bronchitis (manuscript invited for CE), *American Journal of Managed Care*, 2 CME/ACPE  
 2011 Following the Curve: Pharmacokinetic Guided-Dosing of Antimicrobials in Pediatrics, *American College of Clinical Pharmacy*, 1 ACPE  
 2015 Antimicrobial Dosing Challenges in Children, *Making-a-Difference in Infectious Diseases*, 1 ACPE  
 Vaccines Update: Meningococcal B and Pneumococcal, *Making-a-Difference in Infectious Diseases*, 1 ACPE

- 2016 Translating Evidence into Practice: Vancomycin Nephrotoxicity in Pediatrics, American College of Clinical Pharmacy, 1 ACPE  
Best Practices for Pediatric Dosing Strategies: Ahead of the curve! Optimizing Vancomycin Dosing with Pharmacokinetic Modeling, American College of Clinical Pharmacy, 1 ACPE
- 2017 What is Standard for Adding Drug to Pediatric Formulary: Institutions, Systems and PBMs?, American College of Clinical Pharmacology, 1 ACPE  
Optimizing Vancomycin Dosing with Pharmacokinetic Modeling: Focus in Pediatrics, Vietnamese American Medical Association & Southern California Vietnamese Physicians Association, Garden Grove, CA, 1 ACPE
- 2018 Optimizing Vancomycin and Aminoglycoside Dosing in Neonatal and Pediatric Patients on Extracorporeal Life Support (VancoAG-ECLS), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI), Coronado, San Diego  
Vancomycin Pharmacology in Pediatric Patients on ECMO, Extracorporeal Life Support Organization, Scottsdale, Arizona
- 2019 PK/PD Applications in Stewardship, Making-a-Difference in Infectious Diseases, 1 ACPE/CME

#### INTERNATIONAL

- 9/2011 Vancomycin Dosing in Children by Area-Under-the Curve (AUC), Interscience Conference on Antimicrobial Agents and Chemotherapy, 0.5 ACPE
- 4/26/2013 Therapeutic Drug Monitoring in Children, School of Pharmacy Ho Chi Minh City, Viet Nam
- 4/24/2014 Vancomycin: Therapeutic Drug Monitoring in Children and Adults, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
- 11/15/2015 Antimicrobial Dosing Challenges in Pediatric Patients, Pediatric Pharmaceutical Care Workshop in Children's Hospital of Chinese Medical University, Taichung, Taiwan
- 11/15/2015 Professional Development and Training in Pediatric Infectious Diseases: Clinical Pharmacists and Students, Pediatric Pharmaceutical Care Workshop in Children's Hospital of Chinese Medical University, Taichung, Taiwan
- 11/16/2015 The Art and Science of Clinical Pharmacy and Its Current Trend in Research: Pediatric Antimicrobial Stewardship, Grand Rounds, Children's Hospital of Chinese Medical University, Taichung, Taiwan
- 11/17/2015 Pneumonia: Science of Selecting Antimicrobials for CAP, HAP, VAP, & HCAP, Chinese Medical University, Taichung, Taiwan

11/23/2015	Case-Based Seminar on Clinical Pharmacists and Inpatient Medical Care: Pediatric Infectious Diseases, Grand Rounds, Children's Hospital of Chinese Medical University, Taichung, Taiwan
11/24/2015	(Presenting) and Publishing Patient-Oriented Research, Children's Hospital of Chinese Medical University, Taichung, Taiwan
11/25/2015	Pharmacokinetics and Pharmacodynamics of Anti-infection Agents in Pediatrics, Children's Hospital of Chinese Medical University, Taichung, Taiwan
11/25/2015	Non-HIV Viral Infections, Chinese Medical University, Taichung, Taiwan
11/30/2015	Academic File for Advancement of Clinical Faculty, Chinese Medical University, Taichung, Taiwan
10/10/2016	Pharmacology of Aminoglycosides, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam
10/10/2016	Aminoglycoside Therapeutic Drug Monitoring, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam
10/11/2016	Antimicrobial Dosing Challenges in Pediatric Patients, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam
10/11/2016	Pharmacokinetics and Pharmacodynamics of Anti-infection Agents in Pediatrics, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam
10/13/2016	Clinical Preceptorship: Train-the-Trainer Program, Chinese Medical University, Taichung, Taiwan
10/14/2016	Clinical Preceptorship: Train-the-Trainer Program, Taiwan Medical University Taipei, Taiwan
10/15/2016	Optimizing Vancomycin Dosing with Pharmacokinetic Modeling and Bayesian Estimation, Chinese Medical University, Taichung, Taiwan
8/15/2017	What is Standard for Adding Drug to Pediatric Formulary: Institutions, Systems and PBMs?, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health Ho Chi Minh City, Viet Nam
10/2/2017	Generic Antibiotics: Improved Use Using Systematic Clinical Pharmacology, Chengdu Food and Drug Administration, San Diego, CA
10/2/2017	Therapeutic Equivalent Evaluations: US Formulary System, Chengdu Food and Drug Administration, San Diego, CA
4/10/2019	Therapeutic Drug Monitoring (TDM): Overview Vancomycin & Aminoglycosides TDM Vancomycin Dosing in Children by AUC TDM Workshop University Medical Center, District 5, Ho Chi Minh City, Viet Nam, 8 CE

**INSTRUCTION :**

**DIDACTIC  
UNIVERSITY OF CALIFORNIA SANDIEGO**

2009 – 2012

**LECTURER**

SPPS 202A Concepts in Pharmacy Practice: Research  
 SPPS 212A Therapeutics I: Clinical Pharmacokinetics and Pharmacokinetic Alterations in Special Populations  
 SPPS 212B Therapeutics II: Digoxin Pharmacokinetics  
 SPPS 212C Therapeutics III: Mood Stabilizer and Anticonvulsant Pharmacokinetics Pharmacokinetics

2009 – 2015

**EXAMINER**, SPPS 212B & 212C Therapeutics

2010 – 2012

**REFERENCE CO-FACILITATOR**, SPPS 212C Therapeutics

2010 – 2012

**AD-CHAIR (COORDINATOR)**, SPPS 212C Therapeutics

2011 – Present

**LECTURER**, Infectious Diseases Pharmacotherapy Review

2011 – 2012

**LECTURER**

SPPS 208 Study Designs: Pharmacokinetics Study Designs  
 SPPS 249 Principles of Pharmacology and Physiology: Aminoglycosides, Beta-Lactams and Vancomycin

2013 – Present

**LECTURER**

SPPS 212A Therapeutics I: Clinical Pharmacokinetics and Pharmacokinetic Alterations in Special Populations  
 SPPS 212B Therapeutics II: Digoxin Pharmacokinetics  
 SPPS 212C Therapeutics III: Mood Stabilizer and Anticonvulsant Pharmacokinetics Pharmacokinetics  
 SPPS 246 Medical Microbiology and Infectious Diseases Therapeutics: Pediatric Infections, Pneumonia, Vancomycin and Aminoglycosides Clinical Pharmacokinetics and Non-HIV Viral Infections  
 SPPS 249 Principles of Pharmacology and Physiology: Aminoglycosides  
**LECTURER**, SPPS 201 Immunization Training Course: Tetanus, Diphtheria, Pertussis , Dtap/Tdap, Hep A & B, HPV  
**EXAMINER**, Multi-Station Objective Structured Clinical Examination (OSCE)  
**FACILITATOR**, Interprofessional Objective Structured Clinical Examination

2013 – Present

2017 – Present

**INSTRUCTION :**

**DIDACTIC  
WESTERN UNIVERSITY COLLEGE OF PHARMACY**

2002 – 2009

**LECTURER**

PHRM 5501 Pharmacokinetics: Drug Dosing in Renal Diseases ;

Pharmacokinetic Alterations in Special Populations – Children, Geriatrics, and Obesity ; Drug Dosing in Cardiovascular Diseases, Pharmacokinetic Drug Interactions, Therapeutic Drug Monitoring  
 PHRM 6204 Pharmacy Practice: Digoxin Pharmacokinetics  
 PHRM 6202 Pharmacy Practice: Fluids & Electrolytes  
 PHRM 6205 Pharmacy Practice: Comprehensive Case Presentation ; Digoxin Pharmacokinetics Review ; Review of Fluid & Electrolytes & TPN  
 PHRM 6206 Pharmacy Practice: Case Study (Asthma, Contraception, DVT/PE, Acne)  
 PHRM 6207 Pharmacy Practice: Theophylline Pharmacokinetics  
 PHRM 6210 Foundation: Case presentation – Respiratory Diseases and Total Parenteral Nutrition - Focus on Calculations  
 PHRM 6301 Pharmacy Practice: Otitis Media, Pediatric Infectious Diseases  
 PHRM 6302 Pharmacy Practice: Vancomycin & Aminoglycosides Pharmacokinetics  
 Comprehensive Review: Review of Calculations and Applied Pharmacokinetics

2004 – 2009

**COURSE CHAIR**, PHRM 5501 *Pharmacokinetics* and PHRM 6206 Pharmacy Practice: Respiratory & Endocrine Diseases

2004 – 2009

**WORKSHOP LEADER AND FACILITATOR**

PHRM 5501 Pharmacokinetics: Workshops 1 – 8  
 PHRM 6206 Pharmacy Practice: Case Study (Asthma, Contraception, DVT/PE, Acne)  
 PHRM 6210: Comprehensive Case Study  
 PHRM 6301 Pharmacy Practice: Case Study (*Pneumonia, Cellulitis*)  
 PHRM 6306: Comprehensive Case Study (*Leukemia, Tumor Lysis Syndrome, Anemia/Thrombocytopenia, Neutropenic Fever*)

2004 – 2009

**EVALUATOR AND CASE FACILITATOR**

PHRM 5501 Pharmacokinetics: Block orientation, review, quiz and examination  
 PHRM 5113 Pharmacy Practice: Objective Structured Clinical Evaluation  
 PHRM 6205 Foundation: Objective Structured Clinical Evaluation  
 PHRM 6210 Pharmacy Practice: Objective Structured Clinical Evaluation, Comprehensive Case (Depression, Hypertension, Anemia, Hypothyroidism)  
 PHRM 6306 Pharmacy Practice: Objective Structured Clinical Evaluation

**INSTRUCTION:**

**EXPERIENTIAL**

2001 – 2010	<b>PRECEPTOR</b> , Acute Care Medicine APPE for 83 Pharmacy Students from Western University and UC San Francisco, Long Beach Memorial Hospital
2002 – 2008	<b>PRECEPTOR</b> , Infectious Diseases and Pharmacokinetics Rotation for 32 PGY-1 Residents and International Pharmacists, Long Beach Memorial Hospital
2009 – Present	<b>INITIATOR AND DEVELOPER</b> , Los Angeles and Orange County Experiential Program for UC San Diego Pharmacy Students, Completed 24 New Site Affiliations and Procured over 100 Advanced Pharmacy Practice Experiences (APPE)
2009 – Present	<b>PRECEPTOR</b> , Acute Care Medicine APPE for over 45 Students from UC San Diego, Long Beach Memorial Hospital,
2017 – Present	<b>DIRECTOR</b> , Los Angeles and Orange County Experiential Program for UC San Diego Pharmacy Students

**STUDENT, RESIDENT & FACULTY MENTORSHIP**

2000 – Present	<b>RESEARCH MENTOR</b> , Mentored over 40 UC San Diego Pharmacy and Medical Students (including T32 and T35 Awardees)
2003 – 2008	<b>RESEARCH MENTOR</b> , Mentored 14 Western University Pharmacy Students
2004 – Present	<b>POST-GRADUATE RESEARCH MENTOR</b> , Mentored 30 PGY-1 Pharmacy Practice Residents at Long Beach Memorial and Miller Children’s & Women’s Hospitals and UC San Diego
2007 – 2017	<b>RESEARCH ADVISOR</b> , Guided 10 Pre-Pharmacy & High School Students
2009 – Present	<b>CAREER ADVISOR</b> , Guided over 10 UC San Diego Pharmacy Students
2014 – Present	<b>FACULTY MENTOR</b> , Mentored 5 Pharmacists with Interest in Academic Career and Scholarly Activities

**PUBLICATIONS OR**

1. Elstner E, Linker-Israeli M, Umiel T, **Le J**, et al. Combination of a potent 20-epi-vitamin D<sub>3</sub> analogue (KH1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreased bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. *Cancer Research* 1996;56:3570-3576. [Original laboratory research]
2. Elstner E, Linker-Israeli M, **Le J**, et al. Synergistic decrease of clonal proliferation, induction of differentiation and apoptosis in APL cells after combined treatment with novel 20-epi vitamin D<sub>3</sub> analogs and 9-cis retinoic acid. *J Clin Invest* 1997;99:349-360. [Original laboratory research]
3. de Vos S, Dawson MI, Holden S, **Le J**, et al. Effects of retinoid x receptorselective ligands on proliferation of prostate cancer cells. *The Prostate*



- 1997;32:115-121. [Original laboratory research]
4. Asou H, Koike M, Elstner E, Cambell M, **Le J**, et al. 19-nor vitamin D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. *Blood*. 1998;92:2441-9. [Original laboratory research]
  5. **Le Jennifer**, Nguyen T, Law A, Hodding J. Adverse drug reactions in pediatrics over a 10-year period. *Pediatrics* 2006;118:555-562. [Original clinical research; Role – conceived, analyzed, wrote and supervised entire study]
  6. **Le Jennifer**, Nguyen T, Okamoto M, Lieberman JM. Impact of empiric antibiotic use on the development of infections caused by extended-spectrum beta-lactamase bacterial pathogens in the neonatal intensive care unit. *Pediatric Infectious Diseases Journal* 2008;27:314-318. [Original clinical research]
  7. **Le Jennifer**, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with conventional amphotericin B in neonates. *Pediatric Infectious Diseases Journal* 2009;28:1061-3. [Original clinical research]
  8. **Le Jennifer**, Castanheira M, Burgess DS, McKee B, Iqbal R and Jones RN. Clonal Dissemination of *Klebsiella pneumoniae* Carbapenemase KPC-3 in Long Beach, California. *J Clin Microbiol*. 2010;48(2):623-5. [Case series]
  9. **Le Jennifer**, SanAgustin M, Tran T and Adler-Shohet FC. Complications associated with outpatient parenteral antimicrobial therapy in children. *Clinical Pediatrics (Phila)* 2010;49:1038-43. [Original clinical research]
  10. **Le Jennifer**, Bookstaver B, Rudisill C, Hashem M, Iqbal R, James C, and Sakoulas G. Treatment of meningitis caused by vancomycin-resistant *Enterococcus faecium*: high-dose and combination daptomycin therapy. *Annals of Pharmacotherapy* 2010;44(12):2001-6. [Case series]
  11. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A and **Le Jennifer**. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. *J of Pediatrics* 2011;158(3):422-6. [Original clinical research]
  12. Wang MK, Tran T, Tran V, Padilla L and **Le Jennifer**. Case-control study of risk factors and outcomes associated with neonatal candidiasis. *Journal of Neonatal-Perinatal Medicine* 2011;4:39-43. [Original clinical research]
  13. **Le Jennifer**, McKee B, Srisupha-olarn W and Burgess DS. *In vitro* activity of carbapenems alone and in combination with amikacin against extended-spectrum beta-lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. *Journal of Clinical Medicine Research* 2011;3(3):106-110. [Original research]
  14. Law AV, Jackevicius C, Murray WI, Hess K, Pham DQ, Min DI, and **Le Jennifer**. Impact of a faculty orientation and development committee. *American Journal of Pharmaceutical Education* 2012; 76 (1) Article 3. [Original clinical research]

15. Kook JL, Chao SR, **Le Jennifer** and Robinson PA. Impact of the use of procalcitonin assay in hospitalized adult patients with pneumonia at a community acute care hospital. *Infect Control Hosp Epidemiol* 2012;33(4):424-426. [Original clinical research]
16. **Le Jennifer**, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. *Pediatric Infectious Diseases Journal* 2013;32(4):e155-63. [Original clinical research]
17. **Le Jennifer**, Tran TT, Bui I, Wang MK, Vo A, Adler-Shohet FC. Time to Initiation of Antifungal Therapy for Neonatal Candidiasis. *Antimicrobial Agents and Chemotherapy* 2013;57(6):2550-55. [Original clinical research]
18. Dugan S, **Le Jennifer**, Jew RK. Maximum tolerated osmolarity for peripheral administration of parenteral nutrition in pediatric patients. *JPEN Journal of Parenteral and Enteral Nutrition* 2013; 38(7):847-51. [Original clinical research]
19. Tran TT, El-Ibiary S, Tindula R, Rai N, Nguyen A, and **Le Jennifer**. Unique pharmacist competency program at community-based, teaching hospitals. *Journal of Hospital Administration* 2013; 2(3):119-23. [Original clinical research]
20. Hill SE, Iqbal R, Cadiz CL, and **Le Jennifer**. Foodborne botulism treated with heptavalent botulism antitoxin. *Ann Pharmacother* 2013;47(2):e12. [Case report]
21. **Le Jennifer**, Vaida F, Nguyen E, Adler-Shohet FC, Romanowski GL, Kim J, Vo T, Capparelli EV. Population-based pharmacokinetic modeling of vancomycin in children with renal impairment. *Journal Pharmacol Clin Toxicol* 2014;2(1):1017-27. [Original clinical research]
22. Tremoulet A, **Le Jennifer**, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Chong SI, Melloni C, Gao J, Benjamin DK Jr, Capparelli EV, and Cohen-Wolkowicz M; on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act — Pediatric Trials Network. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. *Antimicrob Agents Chemother* 2014;58(6):3013-3020. [Original clinical research]
23. **Le Jennifer**, Ngu B, Bradley JS, Murray W, Nguyen A, Nguyen L, Romanowski GL, Vo T, and Capparelli EV. Accuracy of vancomycin monitoring in children using Bayesian estimation. *Therapeutic Drug Monitoring* 2014;36(4):510-8. [Original clinical research]
24. Jackevicius CA, **Le Jennifer**, Nazer L, Hess K, Wang J, and Law AV. A formal mentorship program for faculty development. *American Journal of Pharmaceutical Education*, 2014;78(5):100. [Original research]
25. Vivian E, Ikem P, Shiyabola O, Tolson Y, and **Le Jennifer**. Health needs and neighborhood concerns of low income households vulnerable to food insecurity. *Public Health* 2014; 128(8):743–745. [Original clinical research]
26. **Le Jennifer**, Dam Q, Schweizer M, Thienphrapa W, Nizet V, and Sakoulas G. Effects of vancomycin versus nafcillin in enhancing killing of

- methicillinsusceptible *Staphylococcus aureus* bacteremia by human cathelicidin LL-37. *European Journal of Clinical Microbiology & Infectious* 2016;35(9):1441-7. [Original clinical research]
27. **Le Jennifer**, Ny P, Capparelli EVC, Lane JR, Ngu B, Muus R, Romanowski G, Vo T, and Bradley JS. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. *J Pediatric Infect Dis Soc* 2015;4(4):e109-16. [Original clinical research]
28. Wing DA, Rumney PJ, Hindra SS, Guzman L, **Le Jennifer**, and Nageotte MP. Pilot investigation to evaluate compliance and tolerability of cranberry capsules in pregnancy for the prevention of asymptomatic bacteriuria in pregnancy. *J Altern Complement Med* 2015;21(11):700-6. [Original clinical research]
29. Ghonimat IM, Nazer LH, Aqel F, Mohammed MK, Hawari FI, and **Le Jennifer**. Effect of nebulized colistin on the ventilator circuit: a prospective pilot case-control study from a single cancer center. *Mediterr J Hematol Infect Dis* 2015;7(1):e2015032. [Original clinical research]
30. Nazer LH, Rihani S, Hawari FI, and **Le Jennifer**. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant *Acinetobacter baumannii* in critically ill cancer patients: a retrospective cohort study. *Infect Dis (Lond)* 2015;47(11):755-60. [Original clinical research]
31. **Le Jennifer**, Capparelli EV, Wahid U, Wu YS, Romanowski GL, Tran TM, Nguyen A, Bradley JS. Bayesian estimation of vancomycin pharmacokinetics in obese children: matched case-control study. *Clin Ther* 2015 Jun 1;37(6):1340-51. [Original clinical research]
32. Abdel Hadi O, Al Omar S, Nazer LH, Mubarak S, and **Le Jennifer**. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. *J Oncol Pharm Pract* 2016;22(3):448-53. [Original clinical research]
33. Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, **Le Jennifer**, et al. Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. *Pediatr Infect Dis J* 2016;35(7):813-5. [Case report]
34. Kinney A, Bui Q, Hodding J, and **Le Jennifer**. Pharmacy dashboard: an innovative process for pharmacy workload and productivity in real-time. *Hospital Pharmacy* 2017;52(3):198-206. [Original clinical research]
35. Bethencourt DM, **Le Jennifer**, Rodriguez G, Kalayjian RW, and Thomas GS. Minimally-invasive aortic valve replacement via right anterior minithoracotomy and central aortic cannulation: a 13-year experience. *Innovations (Phila)* 2017;12(2):87-94 [Original clinical research]
36. Tran T, Khattar S, Vu TT, Potter M, Hodding J, Kuo GM, and **Le Jennifer**. Impact of pharmacist discharge counseling on hospital readmission and emergency department visit. *Journal of Hospital Administration* 2017;6(2):68-73. [Original clinical research]

37. Avedissian S, Bradley JS, Zhang D, Tran TM, Nguyen A, Bradley E, and **Le Jennifer**. Augmented renal clearance using population-based pharmacokinetic modeling in critically-ill pediatric patients *Pediatric Critical Care Medicine* 2017;18(9):e388-e394. [Original clinical research]
38. **Le Jennifer**, Dam Q, Tran TM, Nguyen A, Adler-Shohet FC, Kim S, Schmidt K, Lieberman JM, and Bradley JS. Complications associated with *Staphylococcus aureus* bacteremia in children over a 25-year period. *Epidemiology & Infection* 2017;145(12):2631-2639 [Original clinical research]
39. **Le Jennifer**, Capparelli EV, Hingtgen S, Scochko S, Black N, Jones RN, Lim Meerana, and Bradley JS. Population pharmacokinetic profile and pharmacodynamic target attainment for Staphylococcal pneumonia in children with cystic fibrosis following single-dose ceftaroline fosamil. *Pediatric Pulmonology* 2017;52(11):1424-1434. [Original clinical research]
40. **Le Jennifer**, Turner N, Deshpande LM, Davis AP, Castanheira M. Case Report of Transient *mcr-1*-harboring *E. coli* with concurrent *S. aureus* bacteremia in Long Beach, California. *Diagnostic Microbiology and Infectious Disease* 2017;89(4):303-304. [Case report]
41. Sauberan JB, Choi B, Paradyse AR, and **Le Jennifer**. Quality and Clinical Outcomes Associated with a Gentamicin Use System Change for Managing Chorioamnionitis. *Journal of Med Syst.* 2017;41(12):202. [Original clinical research]
42. **Le Jennifer**, Poindexter B, Sullivan JE, Laughon M, Delmore P, Blackford M, Yogev R, et al. Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. *Therapeutic Drug Monitoring* 2018;40(1):103-108. [Original clinical research]
43. Sader HS, Mendes RE, **Le Jennifer**, Denys G, Flamm RK, and Jones RN. Antimicrobial Susceptibility of *Streptococcus pneumoniae* from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). *Open Forum Infect Dis.* 2019;6(Suppl 1):S14-S23. [Original research]

**REVIEW AND INVITED ARTICLES** **Le Jennifer** and Tsourounis C. Implanon: a critical review. *Annals of Pharmacotherapy* 2001;35:329-336. [Review article]

45. **Le Jennifer**, Briggs G, McKeown A, Bustillo J. Urinary tract infections during pregnancy. *Annals of Pharmacotherapy* 2004;38:1692-1701. [Review article]
46. **Le Jennifer** and Lipsky M. Management of bacterial rhinosinusitis. *American Journal of Managed Care* 2004;4:S3-11. [Review article]
47. **Le Jennifer** and Lipsky M. Therapeutic management of bronchitis. *American Journal of Managed Care* 2005;5:S3-10. [Review article]
48. **Le Jennifer** and Lieberman JM. Management of community-associated methicillin-resistant *Staphylococcus aureus* infections in children. *Pharmacotherapy* 2006;26:1758-1770. [Review article]
49. **Le Jennifer**, Dodds-Ashley E, Neuhauser MM, Brown J, Gentry C, Klepser ME, et al. Insights from the Society of Infectious Diseases Pharmacist: Consensus

- Review of Aerosolized Antimicrobial Agents Using Evidence-based Pharmacotherapy. *Pharmacotherapy* 2010;30:562-584. [Major article in form of evidenced-based consensus statement by the Society of Infectious Diseases Pharmacists]
50. **Le Jennifer** and Schiller D. Aerosolized delivery of antifungal agents. *Current Fungal Infection Reports* 2010;4:96-102. [Review article]
51. Jahng M and **Le Jennifer**. Daptomycin for treatment of complicated skin and skin structure infections. *Healthy Aging & Clinical Care in the Elderly* 2012:413–25. [Invited Review Article; I invited Dr. Jahng (former pharmacy resident) to serve as first author to support his scholarly career development]
52. Natale S, Bradley JS, Nguyen WH, Tran TM, Ny P, La K, Vivian EM, and **Le Jennifer**. Pediatric obesity: pharmacokinetic alterations and effects on antimicrobial dosing. *Pharmacotherapy* 2017 Mar;37(3):361-378. [Review article]
53. **Le Jennifer**, Bradley JS Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. *J Clin Pharmacol* 2018;58 Suppl 10:S108-S122. [Review article]
54. Mashni O, Nazer L, and **Le Jennifer**. Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing *Klebsiella pneumoniae*. *Ann Pharmacotherapy* 2019;53(1):70-81 [Review article]
55. Nazer LH, Le J. Cost-effective Analysis of Low- versus High-dose Colistin in the Treatment of Multi-drug Resistant Pneumonia in Saudi Arabia. *Int J Clin Pharm.* 2019;41(1):1-2 [Letter to Editor]

## BOOKS AND BOOK CHAPTERS

56. **Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. 19<sup>th</sup> edition. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2012. [Invited author]
57. **Le Jennifer**. Administration and kinetics of drugs. In: *The Merck Manual Home Health Handbook*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2012. [Invited author]
58. **Le Jennifer**. Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2013 (Chapter 36, 528-545). [Invited author and editorial board member]
59. **Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2013 (Chapter 45, 708-717). [Invited author and editorial board member]
60. **Le Jennifer**, Jahng M. Skin and Skin Structure Infections. Ambulatory Care Self-Assessment Program (ACSAP), Book 2: Infection Primary Care; July 15, 2013. [Invited author]
61. **Le Jennifer**. Do I dose medications the same for the obese child as a normal weight child? In: *Curbside Consultation in Pediatric Obesity: 49 clinical questions*. Thorofare, New Jersey: Slack, Inc., April 2014. [Invited author]



62. La K, **Le Jennifer**. What drugs are available to treat obesity in children? In: *Curbside Consultation in Pediatric Obesity: 49 clinical questions*. Thorofare, New Jersey: Slack, Inc., April 2014. [Invited author]
63. **Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9) [Invited author]
64. **Le Jennifer**. Skin and skin structure infection. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9) [Invited author]
65. **Le Jennifer**, Chan D. Neonatal sepsis. In: Electronic Supplement to *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9) [Invited author]
66. **Le Jennifer**, Chan D. Osteomyelitis. In: Electronic Supplement to *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9). [Invited author]
67. Chan D and **Le Jennifer**. Acute otitis media. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9). [Invited author]
68. Chan D and **Le Jennifer**. Pneumonia. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9). [Invited author]
69. **Le Jennifer** and Bradley JS. Pharmacodynamic considerations and special populations – pediatrics. In: *Antibiotic Pharmacodynamics*. New York: Springer Science & Business Media LLC, 2014. [Invited author]
70. **Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2014. [Invited author]
71. **Le Jennifer**. Administration and kinetics of drugs. In: *The Merck Manual Home Health Handbook*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2014. [Invited author]
72. **Le Jennifer** and Bradley JS. Pharmacodynamic considerations and special populations – pediatrics. In: *Antibiotic Pharmacodynamics*. New York: Springer Science & Business Media LLC, 2016, pp 561-597. [Invited author]
73. Finley PR, **Le Jennifer** and Lee KC. Antidepressants. In: *Applied Pharmacokinetic and Pharmacodynamics of Psychopharmacological Agents*. Switzerland: Springer International Publishing Switzerland, 2016. [Invited author]
74. **Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2016. [Invited author]
75. **Le Jennifer**. Administration and kinetics of drugs. In: *The Merck Manual Home Health Handbook*. Whitehouse Station, NJ: Merck Sharp & Dohme

- Corp, 2016. [Invited author]
76. **Le Jennifer**. Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2017 in progress. [Invited author and editorial board member]
77. **Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2017. [Invited author and editorial board member]
78. Lee H and **Le Jennifer**. Urinary tract infections. In: *ACCP's Pharmacotherapy Self-Assessment Programs (PSAP) 2016-2018 Series: Infectious Diseases*, 2017. [Invited author]
79. **Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2017. [Invited author]
80. **Le Jennifer** and Dam Q. Skin and soft tissue infections. In: McGraw Hill and Scott Sutton Naplex Review Guide. New York, NY: McGraw-Hill, 2017, in press. [Invited author]
81. **Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2018. [Invited author]
82. **Le Jennifer**. Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2019. [Invited author]
83. **Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2019. [Invited author]

#### REFEREED CONFERENCE PROCEEDINGS

84. **Le Jennifer**, Nguyen T, Law AV, and Hodding J. Retrospective analysis of adverse drug reactions in hospitalized pediatrics over 10-year period. *Pharmacotherapy* 2005;25(10):1431.
85. Wang J, **Le Jennifer**, Murray W, McGory R. Longitudinal development of pharmacokinetics in the pharmacy curriculum. *American Journal of Pharmaceutical Education* 2006; 70 (3) Article 65; page 14.
86. **Le Jennifer**, Kim J, Taing S, Kildoo CW. Evaluation of empiric antibiotic use in the treatment (of healthcare-associated pneumonia in hospitalized patients. *American Journal of Health-System Pharmacy*; 2007;63(20):1901-2014
87. The FOD working committee (Betageri G, Hess K, Jackevicius C, Law AV, **Le Jennifer**, Min D, Murray W and Pham D - listed in alphabetical order). A model to address faculty development and enrichment: The Faculty Orientation and Development Committee. *American Journal of Pharmaceutical Education* 2009; 73 (4) Article 57; page 96.
88. **Le Jennifer**, Hernandez E, Jahng M, McKamy S. Nephrotoxicity associated with high vancomycin troughs in children. *Pharmacotherapy*



2009;29(10):1273.

89. **Le Jennifer**, Jones RN, Castanheira M, Srisupha-olarn W and Burgess DS. *In vitro* activity of carbapenems alone and in combination with amikacin against extended-spectrum beta-lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. *Pharmacotherapy* 2009;29(10):1273.
90. Wang MW, Padilla L, Song T, Tran V, Tran T, and **Le Jennifer**. Evaluation of risk factors associated with invasive candidiasis in critically ill infants. *Pharmacotherapy* 2009;29(10):1273.
91. Nazer L, Sheikha L, Anabtawi N and **Le Jennifer**. Predictors of Augmented Renal Clearance in Critically-Ill Patients with Cancer. Poster presentation at Society of Critical Care Medicine. *Critical Care Medicine* 2019;47:702.
92. **Le Jennifer**, Le K, Nazareth S, and Seto S. Discrepancies in medication order entry within a dual- computer system. Co-presenter, Poster presentation at ASHP Midyear Meeting, December 2001 in Las Vegas, NV.
93. **Le Jennifer**, Adler-Shohet F, Nguyen C and Lieberman J. Nephrotoxicity Associated with Conventional Amphotericin B in Neonates. Presenter, Poster presentation at the 43rd Annual Meeting of the Infectious Diseases Society of America, October 2005 in San Francisco, CA.
94. **Le Jennifer**, Nguyen T, Law AV, and Hodding J. Retrospective analysis of adverse drug reactions in hospitalized pediatrics over 10-year period. Presenter, Poster presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2005 in San Francisco, CA.
95. Wang J, **Le Jennifer**, Murray W, McGory R. Longitudinal development of pharmacokinetics in the pharmacy curriculum. Co-presenter, Poster presentation at the Annual Meeting of American Association of Colleges of Pharmacy, July 2006 in San Diego, CA.
96. **Le Jennifer**, Nguyen T, Okamoto M, Lieberman JM. Impact of empiric antibiotic use on the development of infections caused by extendedspectrum beta-lactamase bacterial pathogens in the neonatal intensive care unit. Presenter, Poster presentation at the 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2006 in San Francisco, CA.
97. **Le Jennifer**, Adler-Shohet FC, Quist R, Lieberman JM. Disseminated candidiasis in neonates. Presenter, Poster presentation at the 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2006 in San Francisco, CA.

## ABSTRACTS

98. **Le Jennifer**, Kim J, Taing S, Kildoo CW. Evaluation of empiric antibiotic use in the treatment of healthcare-associated pneumonia in hospitalized patients. Co-presenter, Poster presentation at the Annual Meeting of American Society of Health-System Pharmacists, December 2006 in Anaheim, CA; and encore presentation at the Spring Forum of the American College of Clinical Pharmacy, April 2007 in Memphis, TN.
99. **Le Jennifer**, SanAgustin M, Hernandez E, Adler-Shohet FC. Complications associated with outpatient parenteral antibiotic therapy in children. Copresenter, Poster presentation at the Annual Meeting of Infectious Diseases Society of America, October 2007 in San Diego, CA and and encore presentation at the Annual Long Beach Research Symposium, November 2008 in Long Beach, CA.
100. The FOD working committee (Betageri G, Hess K, Jackevicius C, Law AV, **Le Jennifer**, Min D, Murray W and Pham D - listed in alphabetical order). A model to address faculty development and enrichment: The Faculty Orientation and Development Committee. Poster presentation at the Annual Meeting of American Association of Colleges of Pharmacy, July 2009 in Boston, MA.
101. **Le Jennifer**, Castanheira M, Chinn R, Jones RN. Clinical outcomes of infections caused by extended-spectrum  $\beta$ -lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. Presenter, Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009 in San Francisco, CA.
102. Castanheira M, Woosley LN, Brady KM, Jones RN, and **Jennifer Le**. High prevalence of CTX-M-producing isolates and emergence of KPC-encoding genes in the western United States (USA). Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009 in San Francisco, CA.
103. **Le Jennifer**, Hernandez E, Jahng M, McKamy S. Nephrotoxicity associated with high vancomycin troughs in children. Co-presenter, Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009 in San Francisco, CA and encore presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2009 in Anaheim, CA
104. **Le Jennifer**, Jones RN, Castanheira M, Srisupha-olarn W and Burgess DS. *In vitro* activity of carbapenems alone and in combination with amikacin against extended-spectrum beta-bactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. Presenter, Poster presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2009 in Anaheim, CA.
105. Wang MW, Padilla L, Song T, Tran V, Tran T, and **Le Jennifer**. Evaluation of risk factors associated with invasive candidiasis in critically ill infants. Copresenter, Poster presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2009 in Anaheim, CA.

106. Burgess DS, McKee B, Srisupha-olarin W, and **Le Jennifer**. In vitro Activity of Carbapenems Alone and in Combination with Amikacin against KPC-producing *K. pneumoniae*. Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2010 in Boston, MA.
107. **Le Jennifer**, Adler-Shohet FC, Bradley J, Tran T and Lieberman JM. Complications associated with *Staphylococcus aureus* bacteremia in children. Presenter, Poster presentation at the Annual Meeting of Infectious Diseases Society of America, October 2010 in Vancouver, Canada.
108. **Le Jennifer**, Bradley JS, Murray W, Romanowski GL, Nguyen N, Cho S, Natale S, Tran T, Bui I and Capparelli EV. Vancomycin Dosing in Children by Area Under-the Curve (AUC). Presenter, Oral presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2011 in Chicago, IL.
109. **Le Jennifer**, Vaida F, Nguyen E, Adler-Shohet FC, Kim J, Vo T, and Capparelli EV. Population-based Pharmacokinetic Modeling of Vancomycin in Children with Renal Impairment. Presenter, Poster presentation at ID Week Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2012 in San Diego, CA.
110. Ngu B, Capparelli EV, Bradley JS, Murray B, Romanowski GL, and **Le Jennifer**. Accuracy of Vancomycin Monitoring in Children. Presenter, Poster presentation at ID Week Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2012 in San Diego, CA.
111. Abdel Hadi O, Nazer LH, Al Omar S, Mubarak S, Capparelli E, and **Le Jennifer**. Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients. Fourth Regional Congress of Cancer and Blood Disorders of Childhood, Jordan Society of Oncology Pediatrics, November 2012 in Amman, Jordan (**Best Poster Award**).
112. Ghonimat I, Nazer LH, Aqel F, **Le Jennifer**. Ventilator Circuit Obstruction Associated with Aerosolized Colistin. SCCM Annual Meeting, 2013 in San Juan, PR.
113. Ola A, Nazer L, **Le Jennifer**. Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients. Platform presentation at the Virtual Poster Symposium of the American College of Clinical Pharmacy, May 2013. [Encore]
114. Ghonimat I, Nazer L, Aqel E, Hawari F, and **Le Jennifer**. Effect of Aerosolized Colistin on the Ventilator Circuit: A Pilot Case-control Study. Platform presentation at the Virtual Poster Symposium of the American College of Clinical Pharmacy, May 2013 (Finalist for the Best Resident and Fellow Poster Competition). [Encore]
115. Bradley J, **Le Jennifer**, Ramachandra Rao S, Rossi S, Hingtgen S, Farrell M, Capparelli EV. Colistin (COL) Single Dose Pediatric Pharmacokinetics and Renal Safety. Presenter, poster presentation at the Annual Interscience

- Conference on Antimicrobial Agents and Chemotherapy, September 2013 in Denver, CO.
116. Ny P, Capparelli EV, Bradley JS, Lane J, Ngu B, Muus R, Romanowski R, Vo T, and **Le Jennifer**. Characteristics of Nephrotoxicity Associated with Vancomycin Use in Children. Presenter, poster presentation at ID Week Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2013 in San Francisco, CA.
117. Hornik CP, Benjamin DK, Clark RH, Capparelli EV, **Le Jennifer**, Tremoulet A, Cohen-Wolkowicz and Smith BP for the Best Pharmaceuticals for Children Act – Pediatric Trials Network. Ampicillin Exposure and Odds of Seizures in a Large Cohort of Hospitalized Neonates. Poster at the Annual Meeting of the Pediatric Academic Societies, May 2014 in Vancouver, Canada.
118. Adler-Shohet FC, Kleis K, Singh J, Schlechter J, Trent E, Osborne S, Davis AP, Frey-Perkis E, Arrieta A and **Le Jennifer**. Treatment and Outcome of Culture-negative Osteomyelitis in Children. Poster presentation at ID Week Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2014 in Philadelphia, PA.
119. Nazer LH, Rihani S, Hawari FI, and **Le Jennifer**. Microbiological Clearance and Nephrotoxicity Associated with High-dose Colistimethate Sodium (1720). Poster presentation accepted at the 43rd Critical Care Congress of the Society of Critical Care Medicine, January 2015 in Phoenix, AZ.
120. Nguyen WH, Bradley JS, Capparelli EV, Wu YS, Tran TM, Romanowski GL, Adler-Shohet FC, and **Le Jennifer**. Optimal Weight-based Vancomycin Dosing in Obese Children Using Bayesian Estimation. Poster presentation at the University of California San Diego Pediatric Symposium, April 2015 in La Jolla, CA.
121. Tran T, Sajjal K, Vu Tiffany, Potter M, Hodding J, Kuo GM, and **Le Jennifer**. Impact of Pharmacist Discharge Counseling on Hospital Readmission and Emergency Department Visit. Poster presentation at California Health Systems Pharmacist, October 2015 in San Diego, CA
122. Avedissian S, Zhang D, Bradley JS, Nazer L, Nguyen A, Tran T, Bradley E, and **Le Jennifer**. Augmented Renal Clearance Using Vancomycin Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Critically-ill Pediatric Patients. Poster presentation at ID Week Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2016 in New Orleans, LA.
123. Singh S, Lee K, Humber D, Lorentz S, Ma J, Colbert J, Painter N, Fricovsky E, Atayee R, and **Le Jennifer**. An Innovative Process for Systematic Review of Experiential Courses. Poster American Association of Colleges of Pharmacy, June 2017 in Nashville, TN.
124. Tran TT, Pham B, Vo T, Hodding, J and **Le Jennifer**. Innovative Approach to the Medication Verification Process: Role of Pharmacists in Minimizing of Confirmation Bias. Poster presentation at CSHP Seminar 2017, October 2017 in Las Vegas, NV.
125. Avedissian S, Rhodes NJ, Nazer L, Kim Y, Valdez J, Bradley JS, and **Le Jennifer**. Augmented Renal Clearance Using Aminoglycoside

- PopulationBased Pharmacokinetic Modeling With Bayesian Estimation in Children in the Pediatric Intensive Care Unit. Poster presentation at ID Week Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2018 in San Francisco, CA.
126. Sader HS, Mendes RE, **Le Jennifer**, Denys G, Flamm RK, and Jones RN. Antimicrobial Susceptibility of Streptococcus Pneumonia From North America, Europe, Asia, and Lan America: Results from 20 Years of the Sentry Antimicrobial Surveillance Program (1997-2016). Poster presentation at ASM Microbe, June 2018, Atlanta, GA.
127. Nazer L, Sheikha L, Anabtawi N and **Le Jennifer**. Predictors of Augmented Renal Clearance in Critically-Ill Patients with Cancer. Poster presentation at Society of Critical Care Medicine. Critical Care Congress, February 2019 in San Diego, CA.

## POPULAR AND OTHER WORKS

128. **Le Jennifer**. Patient education pamphlet and a drug-herb interaction table of commonly-used herbal medicines. Long Beach Memorial Medical Center, 2001.
129. **Le Jennifer**. Aranesp monograph for pharmacy & therapeutics committee. Peer-reviewed by Susan Vancampen, Neepa Rai; Approved by the Pharmacy & Therapeutics Committee, 2002.
130. **Le Jennifer**. Revision of adult intravenous digoxin guideline for pharmacist-regulated therapies. Peer-reviewed by Ambrose P, Kildoo C, Rai N, Safani M, Tobias S, Van Campen S, Warren V; Approved by: EP/Pacer Subcommittee of Department of Cardiology, October 30, 2003 and Pharmacy & Therapeutics Committee, November 18, 2003. [Clinical practice guideline]
131. **Le Jennifer**, Wachtfogel M, Nazareth S, Chu Kathlynn and Tran K. Chemotherapy monitoring form. Long Beach Memorial Medical Center, 2003. [Clinical practice form]
132. **Le Jennifer**. Physiologic changes that affect drug dosing in the elderly. *Pharmacy Times*. December 2003;26-7. [Review article]
133. **Le Jennifer**. Fluoroquinolones: focus on safety profile. *Pharmacy Times*. September 2004;49-50. [Review article]
134. Medication facts. Adapted from American Academy of Pediatrics. Educational pamphlet for children and parents distributed at health fairs, 2004.
135. **Le Jennifer**. Revision of adult intravenous vancomycin guideline for pharmacist-regulated therapies. Peer-reviewed by Kildoo C, Ambrose P, and Strayer G. Approved by Pharmacy & Therapeutics Committee, October 2005. [Clinical practice guideline]
136. **Le Jennifer**. Acute otitis media. *Rx Consultant*. February 2008;17:1-6. [Review article]
137. **Le Jennifer** and Natale Stephanie. Pharmacokinetic alterations in obese children. Websites Part 1: <https://itunes.apple.com/us/podcast/episode->

[7-part-1/id1175416904?i=1000383843377&mt=2](https://itunes.apple.com/us/podcast/episode-7-part-1/id1175416904?i=1000383843377&mt=2) and Part 2:  
<https://itunes.apple.com/us/podcast/episode-7-part-2/id1175416904?i=1000383843378&mt=2> [Invited by American College of Clinical Pharmacy for iTunes Podcast]

138. **Le Jennifer**, Adler-Shohet F, Nguyen C and Lieberman J. Nephrotoxicity Associated with Conventional Amphotericin B in Neonates. 43rd Annual Meeting of the Infectious Diseases Society of America, October 6-9, 2005 - San Francisco; page 140.
139. Schieszer J. Vancomycin-related renal toxicity in children. *Renal and Urology News*. November 2009. [News article of research study]